Inborn Errors of Metabolism - Study Notes
Lesson summary
Inborn errors of metabolism (IEM) are inherited disorders with specific enzyme defects that impede the normal metabolism of protein, fat or carbohydrate. They can appear at birth or later in life. The main sign is excess storage of a specific metabolite in tissues, organs and blood. Most IEM are rare, but some are life threatening.
History
- 1908: Sir Archibald Garrod introduced the term after studying alkaptonuria, where a gene mutation led to homogentisic acid and black urine.
- 1941: George Beadle and Edward Tatum, using the bread mould Neurospora, proposed the one gene one enzyme theory.
- 1957: Vernon Ingram changed it to one gene one polypeptide, since many proteins have more than one chain.
Biochemical basis
In a pathway R to B to C to D to P with enzymes a, b, c and d, if any enzyme is deficient the previous intermediate accumulates and may be toxic, and less product P is formed. Excess intermediate or its breakdown products are excreted in urine.
Classification
| Group | Examples |
|---|---|
| Amino acid metabolism | Phenylketonuria, alkaptonuria, albinism, homocystinuria |
| Carbohydrate metabolism | Galactosemia, hereditary fructose intolerance, Von Gierke disease |
| Lysosomal storage | Mucopolysaccharidosis, Tay-Sachs, Niemann-Pick, Gaucher's disease |
| Organic acidemia | Methyl malonic acidemia |
| Purine or pyrimidine | Lesch-Nyhan syndrome |
| Peroxisomal | Adrenoleukodystrophy |
| Urea cycle | Citrullinemia, ornithine transcarbamoylase deficiency |
| Metal metabolism | Wilson's disease |
Galactosemia
- Described by Von Reuss in 1908; about 1 in 18,000 live births.
- Galactose comes from lactose in milk and dairy products.
- Type I: GALT (galactose-1-phosphate uridyltransferase), the most severe; type II: GALK1 (galactokinase); type III: GALE (UDP-galactose 4-epimerase).
- Aldose reductase turns galactose into galactitol in the eye, causing cataract.
- Galactose 1-phosphate injures the liver; after 2 to 3 months fatty infiltration and cirrhosis follow; mental retardation, jaundice, vomiting, hypoglycemia, E. coli sepsis.
Von Gierke disease
- Glycogen storage disease type I; patient described in 1929; glucose 6-phosphatase deficiency shown by Carl and Gerty Cori in 1952.
- Glucose 6-phosphate cannot cross the plasma membrane, so glycogen builds up in liver and glycolysis rises, raising pyruvic and lactic acid.
- Fasting hypoglycemia with lactic acidosis, enlarged liver, distended abdomen, doll-like face, high uric acid, hyperlipidemia, ketosis, nose bleeds.
- Treatment: food high in starch.
Hemophilia
- Term coined by Dr. John Conrad Otto in the early 19th century.
- Platelets form a platelet plug; clotting factors form a coagulation cascade ending in a fibrin clot, which acts as a mesh and stops bleeding.
- Nearly 13 clotting factors: I fibrinogen, II prothrombin, IV calcium ions, V labile factor, VII stable factor, X Stuart-Prower factor, XIII fibrin stabilizing factor.
- Sufferers are called hemophiliacs or bleeders; mainly males are affected.
- Hemophilia A: classic form, sex-linked recessive, factor VIII deficiency, about 1 in 10,000 males.
- Hemophilia B: second most common, factor IX dysfunction, also called Christmas disease.
- Symptoms: heavy bleeding from small injuries, slow clotting, internal bleeding, painful swollen joints, bleeding after vaccination. Some patients form inhibitors against the clotting factors used in treatment.
Albinism
- Latin albus means white; little or no colour in skin, hair or eyes.
- Vision defects: photophobia, nystagmus, amblyopia; higher risk of sunburn and skin cancer.
- Melanin is made in melanocytes from tyrosine through DOPA by tyrosinase (diphenol oxidase), a copper-containing enzyme. DOPA becomes DOPA quinone; the commoner product is brown eumelanin, and with cysteine red-yellow pheomelanin forms.
- OCA1: tyrosinase defect (OCA1a no melanin, OCA1b some melanin); OCA2: African descendants and Native Americans, milder; OCA3: TYRP1 gene; OCA4: SLC45A2 protein, East Asian descendants.
- Ocular albinism: eyes only. Oculo-cutaneous albinism: skin and eyes.
Alkaptonuria
- Scribonius (1584) described urine black as ink; Boedeker (1859) used the term alkaptonuria.
- Pathway: phenylalanine to tyrosine to 4-hydroxyphenylpyruvic acid to homogentisic acid to maleylacetoacetic acid.
- Homogentisate 1,2-dioxygenase (homogentisic acid oxidase) is deficient, so homogentisic acid (alkapton) is excreted and darkens in air.
- Ochronosis: dark pigment in connective tissue and the sclera; degenerative arthritis in old age.
- Prevalence 1:100,000 to 250,000; higher in Slovakia and the Dominican Republic. No cure; reduce tyrosine and phenylalanine and take ascorbic acid.
Tay-Sachs disease
- Gangliosides are glycosphingolipids, about 6% of brain lipids, and act as receptors and in cell-cell recognition.
- GM1 to GM2 by beta-galactosidase; GM2 to GM3 by hexosaminidase A.
- A lysosomal storage disease: hexosaminidase A fails, so GM2 accumulates in neuronal lysosomes.
- Muscle weakness, mental retardation, blindness; over 90% show a cherry red spot in the retina. Diagnosed by assaying hexosaminidase A in amniotic fluid. No cure; gene or enzyme replacement therapy only slows it.
Exam tips
- Pair each disease with its enzyme: galactosemia - GALT, Von Gierke - glucose 6-phosphatase, albinism - tyrosinase, alkaptonuria - homogentisate oxidase, Tay-Sachs - hexosaminidase A.
- Remember 1908, 1941, 1952 and 1957.
More for this chapter
Book Back Questions18 textbook MCQs · solved
Additional MCQs15 extra MCQs · solved
Practice TestInteractive · instant score
Book Back TestTest yourself on the textbook set
Additional MCQ TestTest yourself on the extra set
Formula SheetAll key formulas